Drug Profile

Polidocanol - 10xBio

Alternative Names: 10XB 101

Latest Information Update: 18 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 10xBio
Class Obesity therapies; Polyethylene glycols; Sclerosants; Small molecules; Vascular disorder therapies
Mechanism of Action Endothelial cell modulators; Vascular disrupting agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase II Obesity

Most Recent Events

11 Mar 2024 Efficacy and safety data from a phase II trial in Obesity released by 10xBio
18 Oct 2023 10xBio has patent pending for Polidocanol worldwide, prior to October 2023
18 Oct 2023 10xBio has patent protection for Polidocanol worldwide, prior to October 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com